Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.9574 USD
−25.79 M USD
0.00 USD
35.21 M
About Cognition Therapeutics, Inc.
Sector
Industry
CEO
Lisa R. Ricciardi
Website
Headquarters
Purchase
Founded
2007
FIGI
BBG001J2P8S7
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CGTX is 0.6301 USD — it has decreased by −0.62% in the past 24 hours. Watch Cognition Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cognition Therapeutics, Inc. stocks are traded under the ticker CGTX.
CGTX stock has risen by 26.02% compared to the previous week, the month change is a 42.56% rise, over the last year Cognition Therapeutics, Inc. has showed a −61.81% decrease.
We've gathered analysts' opinions on Cognition Therapeutics, Inc. future price: according to them, CGTX price has a max estimate of 14.00 USD and a min estimate of 1.50 USD. Watch CGTX chart and read a more detailed Cognition Therapeutics, Inc. stock forecast: see what analysts think of Cognition Therapeutics, Inc. and suggest that you do with its stocks.
CGTX reached its all-time high on Oct 8, 2021 with the price of 13.8000 USD, and its all-time low was 0.3400 USD and was reached on Oct 11, 2024. View more price dynamics on CGTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CGTX stock is 16.81% volatile and has beta coefficient of 2.95. Track Cognition Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cognition Therapeutics, Inc. there?
Today Cognition Therapeutics, Inc. has the market capitalization of 26.18 M, it has decreased by −6.44% over the last week.
Yes, you can track Cognition Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cognition Therapeutics, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
CGTX earnings for the last quarter are −0.25 USD per share, whereas the estimation was −0.20 USD resulting in a −27.12% surprise. The estimated earnings for the next quarter are −0.19 USD per share. See more details about Cognition Therapeutics, Inc. earnings.
Cognition Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CGTX net income for the last quarter is −9.94 M USD, while the quarter before that showed −7.04 M USD of net income which accounts for −41.13% change. Track more Cognition Therapeutics, Inc. financial stats to get the full picture.
No, CGTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 28.00 employees. See our rating of the largest employees — is Cognition Therapeutics, Inc. on this list?
Like other stocks, CGTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cognition Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cognition Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cognition Therapeutics, Inc. stock shows the sell signal. See more of Cognition Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.